PMID: 15228155Jul 2, 2004Paper

Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau"

Therapeutic Drug Monitoring
Finn Bengtsson

Abstract

TDM applied in psychiatry dates back several decades. The reason for this is that, after the advent of modern clinical psychopharmacology around the middle of the past century, an insight came to common knowledge about the existence of (1) a large interindividual pharmacokinetic (PK) variability for virtually all psychoactive drugs and (2) a worse clinical efficacy not only in inadequate drug concentrations but also in excessively high concentrations. From this concept, the definition of a therapeutic concentration "window" was evidenced for a substantial number of, primarily, antidepressant drugs. However, with the further extensive development of the clinically available pharmacopoeia of psychoactive drugs from the later 1980s until today, the concept of less toxic compounds than before has commonly been launched in the marketing strategies for these newer drugs. This concept also led to the idea that TDM was no longer necessary for the newer types of psychoactive drugs, a position backed up by difficulties in unraveling concentration-effect relationships generally for these drugs in clinical trials. The present survey summarizes the background history for TDM in psychiatry and makes a critical appraisal of why a "lack" of de...Continue Reading

References

Jan 1, 1990·Journal of Pharmaceutical and Biomedical Analysis·S H Wong
Sep 1, 1989·Therapeutic Drug Monitoring·P J Orsulak
May 10, 1985·Journal of Chromatography·T R Norman, K P Maguire
Aug 7, 1971·British Medical Journal·M AsbergD Tuck
Jan 1, 1980·Therapeutic Drug Monitoring·F SjöqvistM Asberg
Aug 1, 1996·Therapeutic Drug Monitoring·K Brøsen
Apr 30, 1999·BMJ : British Medical Journal·O Spigset, B Mårtensson
Apr 11, 2001·Therapeutic Drug Monitoring·J LundmarkF Bengtsson
Mar 27, 2003·Therapeutic Drug Monitoring·Daniel OhmanFinn Bengtsson
Mar 27, 2003·Therapeutic Drug Monitoring·Margareta ReisFinn Bengtsson

❮ Previous
Next ❯

Citations

Jan 16, 2008·European Journal of Clinical Pharmacology·Christoph Hiemke
May 10, 2013·European Journal of Clinical Pharmacology·Erik EliassonMarja-Liisa Dahl
Apr 12, 2008·European Archives of Psychiatry and Clinical Neuroscience·Christoph Hiemke
Nov 11, 2006·Clinical Neuropharmacology·Jessica Fleming, Manoranjenni Chetty
Jan 20, 2006·International Clinical Psychopharmacology·Ann-Charlotte AkerbladLisa Ekselius
Dec 31, 2010·Journal of Clinical Psychopharmacology·Maria D ChermáPer A Gustafsson
Jul 14, 2009·Current Opinion in Nephrology and Hypertension·Wana ManitpisitkulMatthew R Weir
Jan 1, 2008·Patient Preference and Adherence·Ann-Charlotte AkerbladLisa Ekselius
May 11, 2010·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Pål Gjerden
Oct 25, 2013·International Review of Psychiatry·Gudrun HefnerChristoph Hiemke
Jul 4, 2009·Expert Opinion on Drug Metabolism & Toxicology·Harriët M Loovers, Jan van der Weide
Sep 2, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Eveline Jaquenoud SirotPierre Baumann
Nov 14, 2015·Clinical Pharmacology and Therapeutics·S H JangJ A Lazor
Oct 4, 2014·Journal of Food and Drug Analysis·Sheng-Chang WangYu-Li Liu
Jan 31, 2006·Human Psychopharmacology·Jan WålinderFinn Bengtsson
Jul 30, 2015·Acta Clinica Belgica·Innocent HahirwaRaphaël Denooz
Mar 5, 2010·Fundamental & Clinical Pharmacology·Michael RougemontPierre Baumann
Dec 6, 2005·Journal of Psychiatric Research·Matthias J MüllerChristoph Hiemke
Jan 22, 2010·Nordic Journal of Psychiatry·Ulla Knorr, Lars Vedel Kessing
Mar 2, 2016·Epilepsy & Behavior : E&B·Cecilie Johannessen LandmarkSvein I Johannessen
Jul 30, 2015·Thérapie·Zoubir DjeradaFréderic Libert
Dec 21, 2012·Journal of Neural Transmission·S UntereckerB Pfuhlmann
Feb 15, 2020·Expert Opinion on Drug Metabolism & Toxicology·Cecilie Johannessen LandmarkPhilip N Patsalos
Oct 21, 2004·Human Psychopharmacology·Iacopo CancelliMatteo Balestrieri
Dec 25, 2013·Therapeutic Drug Monitoring·Stefan UntereckerBruno Pfuhlmann
Nov 23, 2011·Therapeutic Drug Monitoring·Stefan UntereckerBruno Pfuhlmann
Jun 22, 2012·Clinical Drug Investigation·Stefan UntereckerBruno Pfuhlmann
May 13, 2020·Clinical Pharmacokinetics·Sanne M KloosterboerBirgit C P Koch
Sep 4, 2020·Therapeutic Drug Monitoring·Stine RognstadMimi S Opdal
May 13, 2021·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·C B EapC Hiemke
Sep 1, 2021·Expert Opinion on Drug Metabolism & Toxicology·Espen Molden
Feb 10, 2021·Therapeutic Drug Monitoring·Soraya V GaneshPierre M Bet
Dec 14, 2021·Frontiers in Psychiatry·Xenia M HartGerhard Gründer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.